Mesenchymal Stem Cells - Advances And Applications

 Published On: May, 2013 |    No of Pages: 125 |  Published By: BioInformant | Format: PDF   |   Free Sample Report

Executive Summary
Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases.
MSCs are advantageous over other stem cells types for a variety of reasons: they avoid the ethical issues that surround embryonic stem cell research, and repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogenic transplantation. MSCs reduce both the risks of rejection and complications of transplantation. Recently, there have been advances in the use of autologous mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, bone fractures, and more.
Trend analysis of grant activity, scientific publication rates, and patent applications trends reveal that global research activity involving mesenchymal stem cells (MSCs) increased 112% from 2009 to 2010, and 116% from 2010 to 2011. Of most interest is that this rate of growth accelerated throughout 2011, making mesenchymal stem cells the fastest growing area of stem cell research.
Because mesenchymal stem cell researchers represent a rapidly growing, well-funded research community, this report presents strategies for research supply companies to use to develop high-demand products for this community. A key element of this report is a survey of mesenchymal stem cell (MSC) researchers. This survey reveals critical findings that include:

  • Preferred Tissue Source for MSCs
  • Preferred Species Source for MSCs
  • MSC Product Preferences
  • Most Commonly Utilized MSC Antibodies
  • Terms Used in Online Search (for targeting your ads with precision)
It is also important for bio-pharmaceutical and pharma companies interested in mesenchymal stem cell therapy applications to understand underlying market forces, and in particular, to consider progressive areas of MSC research as opportunistic areas for drug and therapy development. This report presents a range of topics of interest to these companies as well, including how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.
Highlights of this report include: 
  • Charts, Timelines, Metrics and Financials 
  • Rates of MSC Grants, Publications, and Patents
  • Market Characterization and 5-Year Projections
  • Breakdown of MSC Research Activity by Application, Species, Tissue Source
  • Geographical Assessment of Market Demand
  • Competitive Environment Analysis, by MSC Product Supplier
  • Recent Product Evolution and Unmet Market Needs
  • Online Advertising Assessment and Opportunities for Targeted Traffic
  • Revealing Survey of Your Prospective Clients - MSC Scientists
  • End-User Wants, Technical Preferences, Factors Influencing Buying Decisions
  • And Much More...
The market intelligence contained in this report was compiled using a broad range of sources, including: 
  • MSC grant funding (NIH database, DoD database)
  • MSC patents (USPTO)
  • MSC publications (PubMed, Highwire Press)
  • MSC product launch announcements (Google News, Trade Journals)
  • International surveys (electronically distributed end-user surveys)
  • And more
These sources were used to identify recent advances in MSC research applications, explore research priorities by market segment, highlight individual labs and end-users of MSC research products, explore the competitive environment for MSC research products, and provide 5-year growth and trend analysis. As such, this market intelligence report will advantageously position your company to offer competitive MSC products to this rapidly growing, well-funded research community.
You'll also access information on: 
  • Recent Product Evolution
  • Projected Directions for Development
  • Overview of Therapeutic Progress and Insight into Future Applications
  • Detailed Evaluation of Profit Opportunities for Research Product Suppliers
In summary, literature and data concerning the biology and differentiation potential of mesenchymal stem cells (MSCs) has become huge in less than 10 years, now totaling nearly 13,000 publications, although some data does present as contradictory, suggesting a heterogenic nature for MSC populations depending on source tissue, species, and donor characteristics. MSCs appear to be an exceptionally promising tool for cell therapy because of their unusual characteristics, which partially mimic those of embryonic stem cells, but have advantages in terms of availability, expandability, transplantability, and ethical implications.
Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as from their ability to migrate to sites of tissue injury/inflammation or tumor growth. These localization properties present a promising strategy for targeted introduction of therapeutic agents through MSC gene therapy. In addition, MSCs possess strong immunosuppressive properties that medical researchers are exploiting for both autologous as well as heterologous therapies.
Characterized by these properties, it not surprising that trend analysis reveals rapid increases in research activity involving mesenchymal stem cells. With scientific publication rate increases of 112% year-over-year from 2009 to 2010, and 116% from 2010 to 2011, this report will help you understand and profit from the mesenchymal stem cell (MSC) product market – the fastest growing area of stem cell research.

Key Strategies and Findings

It is now generally accepted within the scientific community that the term “mesenchymal stem cell” is the proper term for use in publication involving peer review. However, existence of alternative nomenclature for the cell type include:
1. Mesenchymal Stem Cell
2. Marrow Stromal Cell
3. Multi-potent Stromal Cell
4. Colony-Forming Unit-fibroblasts (CFU-f)

For purposes of marketing products to this research community, it is recommended that the term “mesenchymal stem cell” be incorporated into the product title. However, for purposes of optimal website traffic flow, pages that feature mesenchymal stem cell (MSC) products should be designed to collect traffic flow resulting from searches for all four of the descriptive names. In addition, the abbreviations “MSC” and “MSCs” should be considered for search optimization as well.

In the trailing twelve months, rates of research exploring directed differentiation of MSCs toward extra-mesenchymal lineages comprised only 6.4% of MSC-directed differentiation research, while rates of research exploring directed differentiation of MSCs toward intramesenchymal lineages comprised 93.6 percent.

Currently, the interdisciplinary orthopedics market is sized at US $100 million annually, but it is expected to surpass the $3 billion mark within the next decade.1 As orthopedic problems ranging from back pain to osteoporosis plagues 75 million Americans, or approximately a quarter of the US population, it is apparent that the demand for MSCbased orthopedic treatments will continue to rise. Bio-pharmaceutical and pharma companies will consider development of MSC-based orthopedic therapies a priority area for research and development due to the high valuation of the orthopedics market and its accelerating growth.

Currently, the US Center for Disease Control (CDC) estimates that approximately 24 million adults in USA have diabetes, mostly type-2 diabetes that is associated with a poor diet and lack of exercise. More frightening, however, is that the CDC projects that a third of the US population will have diabetes by 2050. Clearly, MSC-based treatments for diabetes will be a major medical priority for the next several decades.

The application receiving the most attention across the research community is the use of MSCs in transplantation for site-specific repair, particularly osteochondral and myocardial repair.

At this time, Millipore and Trevigen are the only companies that offer Adipogenic and Osteogenic Kits for use with rat mesenchymal stem cells within the US. Millipore launched its rat MSC differentiation kits in 2007, and Trevigen launched its in 2009. However, several other companies, such as Thermo Scientific and Invitrogen, offer Adipogenic and Osteogenic Kits for use with human mesenchymal stem cells. Cyagen offers Adipogenesis and Osteogenesis Kits for use with rat mesenchymal stem cells, but only distributes its products within China.

Research with adult-derived MSCs is nearly eight times as common as research with fetalderived MSCs.

The second interesting finding is the high relative frequency of MSC research performed with bone marrow-derived (53.1%) and adipose-derived (22.1%) MSCs.

The intriguing finding from this industry report is the concentrated study of mesenchymal stem cells within the United States, Europe, and Asia.

In 2010, the annual growth rate for MSC research publications was 112%. In 2011, the annual growth rate for MSC research publications was 116%.

Using an exponential best-fit line (which is more accurate than a linear, polynomial, logarithmic, power, or moving average best-fit line), with an r2 value of 0.9685, five-year projection data predicts that mesenchymal stem cell publications will reach approximately 73,308 annually by 2016. If the exponential growth observed over the previous five years continues, the predicted increase in publication rates for the coming five years would represent approximately an 8.5-fold increase in published mesenchymal stem cell research activity from 2010 to 2015.

At this time, there is market demand for serum-free supplements qualified for use with MSCs, but relatively few commercial suppliers.

There is only one commercial provider of synovium-derived mesenchymal stem cells, Thermo Scientific, and this company offers human synovium-derived mesenchymal stem cells. To date, no commercial provider exists for synovium-derived rat mesenchymal stem cells, despite demonstrated advantages of MSCs derived from this source. As such, this may represent a unique product opportunity for research products companies to consider.

The top search term “Mesenchymal Stem Cell” does not have nearly as many Adword competitors (three) as several of the lower ranking search terms (for which there are seven to eight competitors, in some cases). Frequently sought search phrases used by scientists that currently have no research product companies competing for them include: MSC and MSC Ab. Research product companies can strategically claim market share by using Adwords campaigns focused around language used by scientists. (For specific suggestions,see Full Report.)


I. Abstract

II. Overview
A. Definition
B. Alternative Nomenclature
C. Identification
1. Characteristics
2. Functional Attributes
D. Benefits Relative to Other Stem Cell Types

III. Sources
A. Fetal
B. Adult

IV. Cell Types Derived from MSCs

V. Applications
A. Basic Research Applications
1. Directed Differentiation of Autologous MSCs to Intra-Mesenchymal Lineages
2. Directed Differentiation of Autologous MSCs to Extra-Mesenchymal Lineages
B. Supporting Hematopoietic Cells
C. Gene Transfer Applications
D. Cell Transplantation for Site-Specific Repair
1. Overview
2. Major Applications
a. Osteogenic-Focused Research Labs
b. Myogenic and Myocardial Repair
c. Neural Repair
c. Pancreatic Repair
E. Topical Therapy and Use of MSCs in Wound Healing
F. Use of MSC in 3-D Scaffolds for Tissue Engineering Applications
G. Drug Delivery Applications: Engineered MSCs as Carriers of Anti-Cancer Drugs
H. Drug Screening
I. MSC-mediated Inhibition of Immune Effector Cells

VI. Application Priorities
A. Overall
B. By Segment
1. Academic
2. Biotechnology
3. Pharmaceutical

VII. Companies Offering Human MSC Research Products
A. Abcam
B. BD Biosciences
C. Celprogen
D. Cyagen Biosciences (China only)
E. Invitrogen
F. LGC Standards/ATCC
G. Lonza
H. Millipore
I. Miltenyi Biotec
J. PAA - The Cell Culture Company
K. PromoCell
L. SA Biosciences
M. ScienCell Research Laboratories
N. STEMCELLTechnologies
O. Thermo Scientific
P. R&D Systems

VIII. Companies Offering Rodent MSC Research Products

(Note: Eight companies currently offer rat MSC products: Cell Applications, Celprogen, Cyagen Biosciences, Genlantis, Millipore, Miltenyi Biotec, ScienCell Research Laboratories, and Trevigen.)

However, five were profiled in the previous section, leaving three to profile below as limited providers of rat MSC products.)

A. Cell Applications
B. Genlantis
C. Trevigen

IX. Analysis of MSC Research Activity
A. By Tissue Source of Origin
B. By Clinical Application
C. By Species Source
D. By Geographical Region

X. Market Trend Analysis
A. Scientific Publication Rate Analysis
1. Historical 10-Year Analysis
2. Future Five-Year Projection
B. Grant Trend Rate Analysis
1. Historical 10-Year Analysis
2. Future Five-Year Projection
C. Patent Analysis

XI. Mesenchymal Stem Cells as Tools for Drug Discovery
A. Companies Developing Toxicology Screening Platforms for Stem Cells
B. Potential Drug Screening Advantages of Mouse MSCs
1. Acquisition, Handling, and Differentiation Advantages
2. Genetic Manipulation of MSCs
3. Potential for Genetically Engineered MSC Reporter Lines

XII. Serum Free Supplements for Use in MSC Research
A. Invitrogen, Inc.
B. Celprogen
C. Millipore, Inc.
D. Stem Cell Technologies
E. US Patent 7109032: Serum-free medium for mesenchymal stem cells (Genoa, IT)
XIII. End-User Preferences (Scientist Panel)
A. Source Preference
B. Species Preference
C. MSC Product Preferences
D. Most Commonly Used MSC Antibodies
E. Common Terms Used for Online Product Search
XIV. Research Product Opportunities and Suggestions
A. Rat MSCs Derived from Synovium
B. Novel MSC Differentiation Kits
C. Mesenchymal Stem Cell Expansion Media
D. Antibodies to Mesenchymal Stem Cell Markers
E. Mesenchymal Growth Factors
F. Monoclonal Antibodies and Kits for Phenotyping MSCs
G. Chips for MicroArray Analysis of Gene Expression in MSCs

XV. Potential Labs/Customers
A. General MSC Research Labs
B. Osteogenic-Focused Research Labs
C. Myogenic- and Myocardial-Focused Research Labs
D. Adipogenic-Focused Research Labs
E. Neuronal-Focused Research Labs
F. Immunology-Focused Research Labs
G. National Institutes of Health (NIH) Labs
H. Commercial Labs

XVI. Conclusions

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.